BIOAGE LABS Aktie

>BIOAGE LABS Aktienkurs

6.4 EUR -6.6% (Tradegate)

Ask: 6.6 EUR / 904 Stück

Bid: 6.45 EUR / 933 Stück

Tagesumsatz: 12279 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

BIOAGE LABS Aktie über LYNX handeln

Intraday

1 Jahr

>BIOAGE LABS Performance

1 Woche: +50,2%

1 Monat: +44,8%

3 Monate: +53,1%

6 Monate: +74,4%

1 Jahr: 0%

laufendes Jahr: 0%

>BIOAGE LABS Aktie

Name:

BIOAGE LABS INC. O.N.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US09077V1008 / A40D7P

Symbol/ Ticker:

Y7G (Frankfurt) / BIOA (NASDAQ)

Kürzel:

FRA:Y7G, ETR:Y7G, Y7G:GR, NASDAQ:BIOA

Index:

Webseite:

https://bioagelabs.com/

Profil:

BioAge Labs Inc. is a biotechnology company focuse..
>Volltext..

Marktkapitalisierung:

234.3 Mio. EUR

Unternehmenswert:

-10.34 Mio. EUR

Umsatz:

3.32 Mio. EUR

EBITDA:

-78.38 Mio. EUR

Nettogewinn:

-67.96 Mio. EUR

Gewinn je Aktie:

-1.92 EUR

Schulden:

7.52 Mio. EUR

Liquide Mittel:

189.47 Mio. EUR

Operativer Cashflow:

-49.36 Mio. EUR

Bargeldquote:

13.02

Umsatzwachstum:

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

BIOAGE LABS

Letzte Datenerhebung:

26.10.25

>BIOAGE LABS Kennzahlen

Aktien/ Unternehmen:

Aktien: 35.85 Mio. St.

Frei handelbar: 58.71%

Leerverk. Aktien: 1.93%

Rückkaufquote: -80.23%

Mitarbeiter: 64

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Neutral

Kursziel: -2.96%

Bewertung:

KGV: -

KGV lG: -

KUV: 55.51

KBV: 1.02

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 95.34%

Gewinnmarge: -2045.74%

Operative Marge: -2364.2%

Managementeffizenz:

Gesamtkaprendite: -32.48%

Eigenkaprendite: -35.88%

>BIOAGE LABS Peer Group

Es sind 596 Aktien bekannt.

>BIOAGE LABS Chart & Kurs - NASDAQ

>BIOAGE LABS News

27.10.25 - 00:00	BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? (Fool)
	The clinical-stage biotech is working on a new type of weight management drug....

22.10.25 - 17:06	Citigroup says shares of this obesity drug biotech could nearly double (CNBC)
	BioAge Labs' novel obesity treatment could boost the biotechnology company's stock, the Wall Street bank says....

02.10.25 - 22:48	BioAge Labs files $250M mixed securities shelf (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.09.25 - 15:33	HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor (PR Newswire)
	BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technology platform, highlighting the value of DEL to accelerate innovative drug development. The initiation of the BGE-102 Phase 1 clinical......

20.08.25 - 22:33	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire EN)
	EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:...

15.08.25 - 15:03	BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire EN)
	First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile...

07.08.25 - 05:48	BioAge Labs (BIOA) Q2 Revenue Hits $2.4M (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.25 - 23:48	BioAge Labs GAAP EPS of -$0.60 misses by $0.04, revenue of $2.41M beats by $1.83M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.25 - 22:33	BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire EN)
	Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end...

22.06.25 - 00:03	BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions (GlobeNewswire EN)
	Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy...

17.06.25 - 15:03	BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank (GlobeNewswire EN)
	Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases...

29.05.25 - 15:03	BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic (GlobeNewswire EN)
	IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end...

27.05.25 - 22:33	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire EN)
	EMERYVILLE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:...

06.05.25 - 22:33	BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire EN)
	RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided business updates and reported its first quarter 2025 financial results....

20.03.25 - 21:54	BioAge Labs GAAP EPS of -$6.63 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

20.03.25 - 21:33	BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 (GlobeNewswire EN)
	Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25...

11.03.25 - 02:33	Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA (PR Newswire)
	LOS ANGELES, March 10, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ: BIOA) for violations of the federal securities laws. Shareholders who purchased the Company's securities pursuant and/or......

10.03.25 - 23:36	BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit (PR Newswire)
	NEW YORK, March 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to the registration statement for BioAge's initial public offering conducted on September 26, 2024......

10.03.25 - 10:45	BioAge Labs, Inc. Class Action: The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - BIOA (PR Newswire)
	NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA). Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff......

10.03.25 - 07:00	BIOA Final Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, March 10, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ: BIOA) for violations of the federal securities laws. Investors......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die meisten freien Schriftsteller sind nur Nebenerwerbsschriftsteller. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram